Strong Market Position Minapharm Pharmaceuticals is a leading biopharmaceutical company in Egypt and actively expanding across the MENA region, presenting significant growth opportunities in emerging markets for partners interested in regional expansion and distribution.

Strategic Investment & Expansion Recent approvals from the African Development Bank and ongoing investments in new facilities in Cairo and Berlin signal the company's commitment to growth and innovation, making it a promising partner for suppliers of advanced bioprocessing equipment and research collaborations.

Advanced Biotech Focus With a strong immunotherapy pipeline and expertise in cellular engineering, Minapharm represents a valuable partner for companies offering next-generation biologics, gene therapies, and customized research tools targeting high-growth biotech sectors.

Global R&D Capabilities The company's integration with its Berlin-based subsidiary ProBioGen and joint biotech projects create opportunities for collaborative development, licensing, and technology transfer agreements in innovative biopharmaceuticals.

Financial Stability and Growth Generating revenue between $25 million and $50 million, coupled with recent funding support, positions Minapharm as a stable partner for expansion into new therapeutic areas and for sourcing cutting-edge manufacturing solutions.